Wedbush raised the firm’s price target on Pharvaris (PHVS) to $27 from $25 and keeps an Outperform rating on the shares. The firm notes management reiterated key clinical milestones which includes potential readout timing for the RAPIDe-3 study of deucrictibant in Q1 2026, and CHAPTER-3 remains on track for the second half of 2026. Also notable in the update, Pharvaris secured tQT study waivers for both the XR and IR formulations, Wedbush adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris price target lowered to $25 from $28 at Cantor Fitzgerald
- Pharvaris: Strong Buy Rating Backed by Regulatory Success and Promising Clinical Progress
- Pharvaris reports Q1 EPS EUR (0.85) vs. EUR (0.52) last year
- Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials
- Pharvaris initiated with an Overweight at Cantor Fitzgerald